MADRID, 11 Abr. (EUROPA PRESS) –
The rating agency Axesor has decided to maintain Pharma Mar’s long-term credit rating at ‘BB’ with a stable trend, as the company communicated to the National Securities Market Commission (CNMV) on Tuesday.
The pharmaceutical group closed 2022 with a net profit of 49.3 million euros, representing a 46% drop compared to the previous year, while total revenue reached 196 million euros, 14% less than the 229 million of 2021.
This difference is mainly due to non-recurring revenues recorded in 2021 and, to a lesser extent, to the change in regulations in France that regulate the prices of drugs available through the compassionate access authorization system.
Of the total revenue generated by the company in 2022, 92% originates outside of Spain.
Despite the decrease in profit, Pharma Mar will distribute a dividend of 0.65 euros gross per share on account of the results of 2022.
